CRISPR/Cas9 therapeutics: progress and prospects
10.1038/s41392-023-01309-7 · doi-reference
Targeting protein modifications in metabolic diseases: molecular mechanisms and targeted therapies
10.1038/s41392-023-01439-y · doi-reference
Post-translational modifications of proteins in cardiovascular diseases examined by proteomic approaches
10.1111/febs.17108 · doi-reference
Protein post-translational modifications: In silico prediction tools and molecular modeling
10.1016/j.csbj.2017.03.004 · doi-reference
Recent advances in predicting and modeling protein-protein interactions
10.1016/j.tibs.2023.03.003 · doi-reference
CRISPR-Cas guides the future of genetic engineering
10.1126/science.aat5011 · doi-reference
The Methods Employed in Mass Spectrometric Analysis of Posttranslational Modifications (PTMs) and Protein-Protein Interactions (PPIs)
10.1007/978-3-030-15950-4_10 · doi-reference
Modulation of poly(ADP-ribose) polymerase-1 (PARP-1)-mediated oxidative cell injury by ring finger protein 146 (RNF146) in cardiac myocytes
10.2119/molmed.2014.00102 · doi-reference
Allosteric activation of the RNF146 ubiquitin ligase by a poly(ADP-ribosyl)ation signal
10.1038/nature13826 · doi-reference
Protein neddylation and its role in health and diseases
10.1038/s41392-024-01800-9 · doi-reference
Cullin-associated and neddylation-dissociated 1 protein (CAND1) governs cardiac hypertrophy and heart failure partially through regulating calcineurin degradation
10.1016/j.phrs.2022.106284 · doi-reference
RhoBTB1 protects against hypertension and arterial stiffness by restraining phosphodiesterase 5 activity
10.1172/jci123462 · doi-reference
Coenzyme Q10 Mitigates Myocardial Infarction by Modulating HDAC4 O-GlcNAcylation
10.1002/biof.70085 · doi-reference
Modification of p53 with O-linked N-acetylglucosamine regulates p53 activity and stability
10.1038/ncb1470 · doi-reference
Overexpression of p53 due to excess protein O-GlcNAcylation is associated with coronary microvascular disease in type 2 diabetes
10.1093/cvr/cvz216 · doi-reference
O-glycosylation regulates ubiquitination and degradation of the anti-inflammatory protein A20 to accelerate atherosclerosis in diabetic ApoE-null mice
10.1371/journal.pone.0014240 · doi-reference
Research progress on post-translational modification of proteins and cardiovascular diseases
10.1038/s41420-023-01560-5 · doi-reference
Histone Methyltransferase Dot1L Contributes to RIPK1 Kinase-Dependent Apoptosis in Cerebral Ischemia/Reperfusion
10.1161/jaha.121.022791 · doi-reference
Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain
10.1016/s0960-9822(02)00901-6 · doi-reference
Maternal Exposure to High-Fat Diet Induces Long-Term Derepressive Chromatin Marks in the Heart
10.3390/nu12010181 · doi-reference
Role of sevoflurane in myocardial ischemia-reperfusion injury via the ubiquitin-specific protease 22/lysine-specific demethylase 3A axis
10.1080/21655979.2022.2062535 · doi-reference
Mettl13 protects against cardiac contractile dysfunction by negatively regulating C-Cbl-mediated ubiquitination of SERCA2a in ischemic heart failure
10.1007/s11427-022-2351-1 · doi-reference
METTL13 Methylation of eEF1A Increases Translational Output to Promote Tumorigenesis
10.1016/j.cell.2018.11.038 · doi-reference
The dual methyltransferase METTL13 targets N terminus and Lys55 of eEF1A and modulates codon-specific translation rates
10.1038/s41467-018-05646-y · doi-reference
The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor
10.1016/s0008-6363(03)00500-5 · doi-reference
Histone lysine methylation and congenital heart disease: From bench to bedside (Review)
10.3892/ijmm.2017.3115 · doi-reference
Protein Arginine Methyltransferases in Cardiovascular and Neuronal Function
10.1007/s12035-019-01850-z · doi-reference
Arginine methylation of METTL14 promotes RNA N(6)-methyladenosine modification and endoderm differentiation of mouse embryonic stem cells
10.1038/s41467-021-24035-6 · doi-reference
Histone methylation: a dynamic mark in health, disease and inheritance
10.1038/nrg3173 · doi-reference
Investigators, Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
10.1056/nejmoa1911303 · doi-reference
SIRT1 mediates the inhibitory effect of Dapagliflozin on EndMT by inhibiting the acetylation of endothelium Notch1
10.1186/s12933-023-02040-x · doi-reference
Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities
10.1016/j.mam.2018.07.001 · doi-reference
Endothelial to Mesenchymal Transition in Cardiovascular Disease: JACC State-of-the-Art Review
10.1016/j.jacc.2018.09.089 · doi-reference
Deacetylation-dependent regulation of PARP1 by SIRT2 dictates ubiquitination of PARP1 in oxidative stress-induced vascular injury
10.1016/j.redox.2021.102141 · doi-reference
Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders
10.1007/s12012-018-9462-2 · doi-reference
Poly(ADP-ribose) polymerase 1 (PARP1) in atherosclerosis: from molecular mechanisms to therapeutic implications
10.1002/med.21300 · doi-reference
Restoration of mutant hERG stability by inhibition of HDAC6
10.1016/j.yjmcc.2018.01.009 · doi-reference
Histone deacetylase 6 inhibitor tubastatin A attenuates angiotensin II-induced hypertension by preventing cystathionine gamma-lyase protein degradation
10.1016/j.phrs.2019.104281 · doi-reference
Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A
10.1021/ja102758v · doi-reference
Tubastatin A suppresses renal fibrosis via regulation of epigenetic histone modification and Smad3-dependent fibrotic genes
10.1016/j.vph.2015.04.006 · doi-reference
